Edwards Lifesciences: Q2 Earnings Insights

Shares of Edwards Lifesciences EW moved higher by 3.5% in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share decreased 75.36% year over year to $0.34, which beat the estimate of $0.17.

Revenue of $925,000,000 declined by 14.90% year over year, which beat the estimate of $789,420,000.

Looking Ahead

The upcoming fiscal year's EPS expected to be between $1.75 and $1.95.

Q3 revenue expected between $4,000,000,000 and $4,500,000,000.

Details Of The Call

Date: Jul 23, 2020

Time: 05:00 PM

ET Webcast URL: https://event.webcasts.com/starthere.jsp?ei=1335563&tp_key=cabc10f160

Technicals

52-week high: $247.64

52-week low: $66.23

Price action over last quarter: Up 8.39%

Company Overview

Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. Its key products include surgical tissue heart valves, transcatheter valve technologies, surgical clips, catheters and retractors, and monitoring systems used to measure a patient's heart function during surgery. The firm derives about 55% of its total sales from outside the U.S.